WESTON (dpa-AFX) - Biogen Idec (BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab, in which aducanumab demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimer's disease. The company said treatment with aducanumab produced a dose- and time-dependent reduction of amyloid plaque in the brain. Amyloid plaque is believed to play a key role in the development of the symptoms of Alzheimer's disease.
Aducanumab is an investigational compound being developed for the treatment of Alzheimer's disease. Aducanumab is a human recombinant monoclonal antibody (mAb) selected from a population of elderly, healthy donors and cognitively stable patients using Neurimmune's technology platform called Reverse Translational Medicine. Biogen Idec licensed aducanumab from Neurimmune under a collaborative development and license agreement.
Based on the results, the company is advancing the aducanumab clinical program to Phase 3 with plans to initiate enrollment later in the current year.
Copyright RTT News/dpa-AFX
© 2015 AFX News
